Pyroptosis-Related Gene Signature Is a Novel Prognostic Biomarker for Sarcoma Patients. (3rd December 2021)

• Record Type: Journal Article
• Authors: Wei, Dalong; Lan, Xiaoling; Huang, Zhiqun; Tang, Qiang; Wang, Zechen; Ma, Yanfei; Wei, Liuzhi; Wei, Qiuju; Zhao, Jingjie; Shen, Jiajia; He, Siyuan; Song, Jian; Meng, Lingzhang; Tang, Qianli
• Other Names: Xie Zhongqiu Academic Editor.
• Is Part Of: Disease markers. Volume 2021(2021)
• Publication Date: 2021-12-03
• Subjects: Diagnosis -- Periodicals; Biochemical markers -- Periodicals; Pathology -- Periodicals; 616
• DOI: 10.1155/2021/9919842
• Languages: English
• ISSNs: 0278-0240

Abstract

Abstract : Sarcoma is a rare and an extremely aggressive form of cancer that originates from mesenchymal cells. Pyroptosis exerts a dual effect on tumours by inhibiting tumour cell proliferation while creating a microenvironment suitable for tumour cell development and proliferation. However, the significance of pyroptosis-related gene (PRG) expression in sarcoma has not yet been evaluated. Here, we conduct a retrospective analysis to examine PRG expression in 256 sarcoma samples from The Cancer Genome Atlas database. We identified the PRGs that had a significant correlation with overall patient survival in sarcoma by performing a univariate Cox regression analysis. Subsequently, we conducted a LASSO regression analysis and created a risk model for a six-PRG signature. As indicated from the Kaplan–Meier analysis, this signature revealed a significant difference between high- and low-risk sarcoma patients. A receiver operating characteristic curve analysis confirmed that this signature could predict overall patient survival in sarcoma patients with high sensitivity and specificity. Gene ontology annotation and Kyoto Encyclopaedia of Genes and Genomes pathway enrichment analyses revealed that five independent PRGs were closely associated with increased immune activity. Moreover, we also deciphered that increased number of immune cells infiltrated the tumour microenvironment in sarcoma. In brief, the PRG signature can effectively act as novel prognostic biomarker for sarcoma patients and is associated with the tumour immune microenvironment.